Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma

Bevacizumab is used to treat glioblastoma; however, no current biomarker predicts its efficacy. We used an exploratory cohort of patients treated with the radiochemotherapy then bevacizumab or chemotherapy at recurrence (N = 265). Bevacizumab use increased median overall survival (OS) 18.7 vs 11.3 m...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Bertaut, Aurélie, Truntzer, Caroline, Madkouri, Rachid, Kaderbhai, Coureche Guillaume, Derangère, Valentin, Vincent, Julie, Chauffert, Bruno, Aubriot-Lorton, Marie Hélene, Farah, Wahlid, Mourier, Klaus Luc, Boidot, Romain, Ghiringhelli, Francois
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Clinical Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342600/
https://ncbi.nlm.nih.gov/pubmed/27487142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10898
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares